Edgewise Therapeutics

Established in 2017 and based in Colorado, US, Edgewise Therapeutics, Inc. operates as a biopharmaceutical company that focuses on developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company was founded by CSO Alan Russell, Director Badreddin Edris, and Chairman Peter Thompson. The trades under the NASDAQ stock exchange under the ticker symbol EWTX. In January 2024, Edgewise Therapeutics, Inc.  Edgewise Therapeutics medical research and development team focuses on bringing orally bioavailable small-molecule therapies designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (DMD), a severe, degenerative muscle disease that affects protein that connects muscle contraction to the supporting basement membrane around muscle fibers and Becker muscular dystrophy (BMD), a milder form of DMD caused by mutation of dystrophin that results in truncated of the protein. The product pipeline includes EDG-5506, EDG-6289, EDG-002 Program, and EDG-003 Program. EDG-5506 is currently in Phase 1 stage, placebo-controlled, double-blind, Single and Multiple Ascending Dose (SAD and MAD) trial. Edgewise Therapeutics is also developing medicines for other muscle disorders that include slower-onset forms of inherited muscle myopathies such as Limb Girdle Muscular Dystrophies (LGMD) and movement disorders that include spasticity and contractures resulting from multiple sclerosis, spinal cord injury, or stroke. The company's revenue is generated by its sales of products -- medicines and modulators for muscle diseases.

1. Series C

   Dec 3, 2020

   Amount

   $95M

   Investors

   Locked

2. Series B

   Sep 17, 2019

   Amount

   $25M

   Investors

   Locked